LDH-A Antibody (E-9): sc-137243

LDH-A Antibody (E-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects LDH-A protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). LDH-A (E-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The lactate dehydrogenase A (LDH-A) protein plays a crucial role in cellular metabolism by catalyzing the conversion of L-lactate and NAD to pyruvate and NADH, which is the final step of anaerobic glycolysis. This process is vital for energy production, especially in tissues that rely heavily on anaerobic metabolism, such as muscle during intense exercise. The LDH family consists of three isoforms—LDH-A, LDH-B, and LDH-C—each exhibiting distinct tissue distribution patterns; LDH-A is predominantly found in muscle tissue, while LDH-B is primarily expressed in the heart, and LDH-C is restricted to the testis and sperm. The differential expression of these isoforms not only highlights their specific physiological roles but also underscores their potential as biomarkers for various conditions, including germ cell tumors. Notably, the genes encoding human LDH-A and LDH-C are located on chromosome 11, while the LDH-B gene is found on chromosome 12. A deficiency in the LDH-A gene has been associated with exertional myoglobinuria, emphasizing the importance of this protein in muscle function and overall metabolic health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LDH-A Antibody (E-9) References:

1. [The role of tumor markers in the treatment of germ cell tumor].  |  Niwakawa, M. and Tobisu, K. 2001. Gan To Kagaku Ryoho. 28: 1159-65. PMID: 11525037
2. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.  |  Xie, H., et al. 2009. Mol Cancer Ther. 8: 626-35. PMID: 19276158
3. Properties of human testis-specific lactate dehydrogenase expressed from Escherichia coli.  |  LeVan, KM. and Goldberg, E. 1991. Biochem J. 273 (Pt 3): 587-92. PMID: 1996957
4. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways.  |  Allison, SJ., et al. 2014. Oncogenesis. 3: e102. PMID: 24819061
5. Locus determining the human sperm-specific lactate dehydrogenase, LDHC, is syntenic with LDHA.  |  Edwards, YH., et al. 1987. Dev Genet. 8: 219-32. PMID: 2844458
6. Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis.  |  Dong, T., et al. 2017. Sci Rep. 7: 6069. PMID: 28729678
7. Lactate Dehydrogenase-A (LDH-A) Preserves Cancer Stemness and Recruitment of Tumor-Associated Macrophages to Promote Breast Cancer Progression.  |  Wang, S., et al. 2021. Front Oncol. 11: 654452. PMID: 34178639
8. miR-16-5p regulates aerobic glycolysis and tumorigenesis of NSCLC cells via LDH-A/lactate/NF-κB signaling.  |  Arora, S., et al. 2022. Life Sci. 304: 120722. PMID: 35714705
9. LDH-A Promotes Metabolic Rewiring in Leucocytes from the Intestine of Rats Treated with TNBS.  |  Mendoza-Arroyo, B., et al. 2023. Metabolites. 13: PMID: 37512550
10. Lactate dehydrogenase M-subunit deficiencies: clinical features, metabolic background, and genetic heterogeneities.  |  Kanno, T. and Maekawa, M. 1995. Muscle Nerve Suppl. 3: S54-60. PMID: 7603529
11. Methods for the separation of lactate dehydrogenases and clinical significance of the enzyme.  |  Kopperschläger, G. and Kirchberger, J. 1996. J Chromatogr B Biomed Appl. 684: 25-49. PMID: 8906464
12. Lactate dehydrogenase from the hyperthermophilic bacterium thermotoga maritima: the crystal structure at 2.1 A resolution reveals strategies for intrinsic protein stabilization.  |  Auerbach, G., et al. 1998. Structure. 6: 769-81. PMID: 9655830

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-LDH-A Antibody (E-9) has 56 citations in a variety of scientific publications.

Primary antibodies like Anti-LDH-A Antibody (E-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

LDH-A Antibody (E-9) Specifications

Alternate Product Name: LDHA

Product Clone Name: E-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 6-42

Epitope Target: LDH-A

Epitope Species: human

Product Reactivity/Detection: LDH-A

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 56 citations in various scientific publications

Available Conjugates/Forms for LDH-A Antibody (E-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin